Targeted lipid-coated nanoparticles: Delivery of tumor necrosis factor-functionalized particles to tumor cells

Journal of Controlled Release

Volumn 137, Issue 1, 2009, Pages 69-77

  Messerschmidt, Sylvia K E ^a   Musyanovych, Anna ^b   Altvater, Martin ^a   Scheurich, Peter ^a   Pfizenmaier, Klaus ^a   Landfester, Katharina ^b   Kontermann, Roland E ^a  

^a UNIVERSITY OF STUTTGART   (Germany)

^b UNIVERSITY OF ULM   (Germany)

Author keywords

Lipid coating; Polystyrene nanoparticles; Single chain Fv; Targeting; Tumor necrosis factor

Indexed keywords

LIPID COATING; POLYSTYRENE NANOPARTICLES; SINGLE-CHAIN FV; TARGETING; TUMOR NECROSIS FACTOR;

CELL CULTURE; CELL DEATH; CELL MEMBRANES; COATING TECHNIQUES; ETHYLENE GLYCOL; FUNCTIONAL POLYMERS; GLYCOPROTEINS; INTERNET; MACROPHAGES; NANOPARTICLES; POLYETHYLENE GLYCOLS; POLYETHYLENE OXIDES; POLYMERS; POLYSTYRENES; TUMORS;

CYTOTOXICITY;

DIPEPTIDASE; FIBROBLAST ACTIVATION PROTEIN; IMMUNOLIPOSOME; LIPID COATED NANOPARTICLE; LIPOSOME; MACROGOL; NANOPARTICLE; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CELL SURFACE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; HUMAN CELL; LIPID COMPOSITION; NANOENCAPSULATION; NANOPHARMACEUTICS; PRIORITY JOURNAL;

ANIMALS; CELL LINE, TUMOR; CHOLESTEROL; COATED MATERIALS, BIOCOMPATIBLE; CYTOTOXICITY, IMMUNOLOGIC; DRUG CARRIERS; FIBROSARCOMA; HUMANS; IMMUNOGLOBULIN FRAGMENTS; LIPIDS; LIPOSOMES; MEMBRANE PROTEINS; MICE; MODELS, BIOLOGICAL; NANOPARTICLES; PHOSPHOLIPIDS; POLYETHYLENE GLYCOLS; POLYSTYRENES; PROTEIN BINDING; RHABDOMYOSARCOMA; SERINE ENDOPEPTIDASES; TUMOR MARKERS, BIOLOGICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 67349253388     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jconrel.2009.03.010     Document Type: Article

References (38)

1. Alexis F., Rhee J.-W., Richie J.P., Radovic-Moreno A.F., Langer R., and Farokhzad O.C. New frontiers in nanotechnology for cancer treatment. Urol. Oncol. 26 (2008) 74-85
2. Haley B., and Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urol. Oncol. 26 (2008) 57-64
3. Cegnar M., Kristl J., and Kos J. Nanoscale polymer carriers to deliver chemotherapeutic agents to tumours. Expert. Opin. Biol. Ther. 5 (2005) 1557-1569
4. Landfester K. Synthesis of colloidal particles in miniemulsions. Ann. Rev. Mater. Res. 36 (2006) 231-279
5. Bryde S., Grunwald I., Hammer A., Krippner-Heidenreich A., Schiestel T., Brunner H., Tovar G.E., Pfizenmaier K., and Scheurich P. Tumor necrosis factor (TNF)-functionalized nanostructured particles for the stimulation of membrane TNF-specific cell responses. Bioconjug. Chem. 16 (2005) 1459-1467
6. Lejeune F.J., Kroon B.B., Di Filippo F., Hoekstra H.J., Santinami M., Liénard D., and Eggermont A.M. Isolated limb perfusion: the European experience. Surg. Oncol. Clin. N. Am. 10 (2001) 821-832
7. Lejeune F.J., Liénard D., Matter M., and Rüegg C. Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun. 6 (2006) 1-17
8. Seynhaeve A.L., Eggermont A.M., and ten Hagen T.L. TNF and manipulation of the tumor-stromal interface: " ways to make chemotherapy effective". Front. Biosci. 13 (2008) 3034-3045
9. Wajant H., Gerspach J., and Pfizenmaier K. Tumor therapeutics by design: targeting and activation of death receptors. Cytokine Growth Factor Rev. 16 (2005) 55-76
10. Gerspach J., Wajant H., and Pfizenmaier K. Death ligands designed to kill: development and application of targeted cancer therapeutics based on proapoptotic TNF family ligands. Results Probl. Cell Differ. (2009) [Electronic publication ahead of print]
11. van Der Veen A.H., ten Hagen T.L., de Wilt J.H., van Ijken M.G., and Eggermont A.M. An overview on the use of TNFα: our experience with regional administration and developments towards new opportunities for systemic application. Anticancer Res. 20 (2000) 3467-3474
12. Al-Jamal W.T., and Kostarelos K. Liposome-nanoparticle hybrids for multimodal diagnostic and therapeutic applications. Nanomedicine 2 (2007) 85-98
13. De Miguel I., Imbertie L., Rieumajou V., Major M., Kravtzoff R., and Betbeder D. Proofs of the structure of lipid coated nanoparticles (SMBV) used as drug carriers. Pharm. Res. 17 (2000) 817-824
14. Senarath-Yapa M.D., Phimphivong S., Coym J.W., Wirth M.J., Aspinwall C.A., and Saavedra S.S. Preparation and characterization of poly(lipid)-coated, fluorophore-doped silica nanoparticles for biolabeling and cellular imaging. Langmuir 23 (2007) 12624-12633
15. Van Schooneveld M.M., Vucic E., Koole R., Zhou Y., Stocks J., Cormode D.P., Tang C.Y., Gordon R.E., Nicolay K., Meijerink A., Fayad Z.A., and Mulder W.J.M. Improved biocompatibility and pharmacokinetics of silica nanoparticles by means of a lipid coating: a multimodality investigation. Nano Lett. 8 (2008) 2517-2525
16. Torchilin V.P. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J. 11 (2007) E128-147
17. Park J.W., Hong K., Kirpotin D.B., Colbern G., Shalaby R., Baselga J., Shao Y., Nielsen U.B., Marks J.D., Moore D., Papahadjopoulos D., and Benz C.C. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin. Cancer Res. 8 (2002) 1172-1181
18. Sapra P., Moase E.H., Ma J., and Allen T.M. Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted bia anti-CD19 IgG2a or Fab′ fragments. Clin. Cancer Res. 10 (2004) 100-1111
19. Pastorino F., Brignole C., Di Paolo D., Nico B., Pezzolo A., Marimpietri D., Pagnan G., Piccardi F., Cilli M., Longhi R., Ribatti D., Corti A., Allen T.M., and Ponzoni M. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res. 66 (2006) 10073-10082
20. Kontermann R.E. Immunoliposomes for cancer therapy. Curr. Opin. Mol. Ther. 8 (2006) 39-45
21. Joyce J.A. Therapeutic targeting of the tumor microenvironment. Cancer Cell 7 (2005) 513-520
22. Hofmeister V., Schrama D., and Becker J.C. Anti-cancer therapies targeting the tumor stroma. Cancer Immunol. Immunother. 57 (2008) 1-17
23. Messerschmidt S.K.E., Kolbe A., Müller D., Knoll M., Pleiss J., and Kontermann R.E. Novel single-chain Fv′ formats for the generation of immunoliposomes by site-directed coupling. Bioconjug. Chem. 19 (2008) 362-369
24. Musyanovych A., Rossmanith R., Tontsch C., and Landfester K. Effect of hydrophilic comonomer and surfactant type on the colloidal stability and size distribution of carboxyl- and amino-functionalized polystyrene particles prepared by miniemulsion polymerization. Langmuir 23 (2007) 5367-5376
25. Krippner-Heidenreich A., Grunwald I., Zimmermann G., Kühnle M., Gerspach J., Sterns T., Shnyder S.D., Gill J.H., Männel D.N., Pfizenmaier K., and Scheurich P. Single-chain TNF, a TNF derivative with enhanced stability and antitumoral activity. J. Immunol. 180 (2008) 8176-8183
26. Carmona-Ribeiro A.M., and de Moraes Lessa M. Interactions between bilayer membranes and latex. Colloids Surf., A 153 (1999) 355-361
27. Carmona-Ribeiro A.M., and Herrington T.M. Phospholipid adsorption onto polystyrene microspheres. J. Colloid Interface Sci. 156 (1993) 19-23
28. Shanbhag A.S., Jacobs J.J., Black J., Galante J.O., and Glant T.T. Macrophage/particle interactions: effect of size, composition and surface area. J. Biomed. Mater. Res. 28 (1994) 81-90
29. Champion J.A., and Mitragotri S. Shape induced inhibition of phagocytosis of polymer particles. Pharm. Res. 26 (2009) 244-249
30. Champion J.A., and Mitragotri S. Role of target geometry in phagocytosis. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 34930-34934
31. Horowitz S.M., Gautsch T.L., Frondoza C.G., and Riley Jr. L. Macrophage exposure to polymethyl methacrylate leads to mediator release and injury. J. Orthop. Res. 9 (1990) 406-413
32. Moghimi S.M. Prolonging the circulation time and modifying the body distribution of intravenously injected polystyrene nanospheres by prior intravenous administration of poloxamine-908. A " hepatic-blockade" event or manipulation of nanosphere surface in vivo?. Biochim. Biophys. Acta 1336 (1997) 1-6
33. Grell M., Douni E., Wajant H., Löhden M., Clauss M., Maxeiner B., Georgopoulos S., Lesslauer W., Kollias G., Pfizenmaier K., and Scheurich P. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 83 (1995) 793-802
34. Schneider-Brachert W., Tchikov V., Neumeyer J., Jakob M., Winoto-Morbach S., Held-Feindt J., Heinrich M., Merkel O., Ehrenschwender M., Adam D., Mentlein R., Kabelitz D., and Schütze S. Compartmentalization of TNF receptor 1 signaling: internalized TNF receptosomes as death signaling vesicles. Immunity 21 (2004) 415-428
35. Micheau O., and Tschopp J. Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes. Cell 114 (2003) 181-190
36. Drummond D.C., Meyer O., Hong K., Kirpotin D.B., and Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 51 (1999) 691-743
37. Romberg B., Hennink W.E., and Storm G. Sheddable coatings for long-circulating nanoparticles. Pharm. Res. 25 (2007) 55-71
38. Pridgen E.M., Langer R., and Farokhzad O.C. Biodegradable, polymeric nanoparticle delivery systems for cancer therapy. Nanomedicine 2 (2007) 669-6880